PHILADELPHIA--(BUSINESS WIRE)--Elixir, a pharmacy benefit management company owned by Rite Aid (NYSE: RAD), has announced details of the next release of its Laker Software technology platform. The upcoming enhancements include new automated workflows, a customer service tool and modernization of the user interface.
Elixir Medical has reported positive findings from a clinical trial investigating its company’s DynamX Coronary Drug-Eluting Bioadaptor compared to a popular drug-eluting stent device already approved for market. The findings, which show the device measures favourably to the Resolute Onyx stent system, were presented at the EuroPCR 2023 conference in Paris.
PHILADELPHIA--(BUSINESS WIRE)--Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD), announced the launch of a specialty generic medication enhancement to its managed copay solutions effective June 1, 2022. The enhancement allows members to receive generic versions of certain specialty medications at a $0 copay and has the potential to provide an average savings of up to $40,000 annually.